{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:28:58Z","timestamp":1790386138759,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,1,5]],"date-time":"2002-01-05T00:00:00Z","timestamp":1010188800000},"content-version":"vor","delay-in-days":1465,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Scand J Immunol"],"published-print":{"date-parts":[[1998,1]]},"abstract":"<jats:p>Intensive chemotherapy for acute leukaemia is followed by a period of severe chemotherapy\u2010induced leukopenia. We used a limiting dilution assay to investigate whether remaining CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> T lymphocytes derived from such leukopenic patients could be activated and undergo clonogenic proliferation. The activation signal in our model was accessory cells (irradiated normal peripheral blood mononuclear cells)\u2003+\u2003phytohaemagglutinin (PHA)\u2003+ interleukin\u20102 (IL\u20102). During severe leukopenia a majority of circulating lymphocytes were CD4<jats:sup>+<\/jats:sup> T cells. Clonogenic proliferating T lymphocytes were detected for all patients. Higher frequencies of clonogenic cells were detected in the CD8<jats:sup>+<\/jats:sup> subset as compared to the CD4<jats:sup>+<\/jats:sup> subset. However, for both subsets frequencies of proliferating cells were decreased compared with healthy individuals. The CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> lymphocytes were also capable of proliferation in response to alloactivation, and accessory cells mainly containing acute myelogenous leukaemia blast were efficient as accessory cells for activation. For the CD4<jats:sup>+<\/jats:sup> cells, increased proliferation was detected in the presence of acute myelogenous leukaemia (AML) blasts compared with normal accessory cells. Based on our results we conclude that: (1) although acute leukaemia patients with therapy\u2010induced leukopenia have both a quantitative and a qualitative T\u2010cell defect, (2) the remaining T\u2010cell population includes a subset capable of clonogenic proliferation. However, (3) proliferation of the clonogenic CD4<jats:sup>+<\/jats:sup> cells can be modulated by AML blasts.<\/jats:p>","DOI":"10.1046\/j.1365-3083.1998.00254.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T20:09:43Z","timestamp":1047499783000},"page":"54-62","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["T\u2010Lymphocyte Functions in Acute Leukaemia Patients with Severe Chemotherapy\u2010Induced Cytopenia: Characterization of Clonogenic T\u2010Cell Proliferation"],"prefix":"10.1111","volume":"47","author":[{"family":"Bruserud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ulvestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Berentsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Bergheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Nesthus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,1,5]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08407.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb05027.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400574"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609054849"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.5.1710.1710"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410063311402"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(05)80204-5"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.Supplement_2.S322"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.Supplement_1.S43"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","unstructured":"YoungLS. Management of infections in leukemia and lymphoma. In: Rubin RH Young LS eds. Clinical Approach to Infections in the Compromised Host (3rd edn). New York: Plenum Medical Book Company 1994:55179.","DOI":"10.1007\/978-1-4615-2490-8_21"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0952-7915(95)80097-2"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0966-842X(94)90112-I"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","unstructured":"Van Der MeerJWM. Defects in host defense mechanisms. In: Rubin RH Young LS eds. Clinical Approach to Infections in the Compromised Host (3rd edn). New York: Plenum Medical Book Company 1994:3366.","DOI":"10.1007\/978-1-4615-2490-8_3"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1976.tb03563.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04981.x"},{"key":"e_1_2_6_17_2","first-page":"1910","article-title":"Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukaemia","volume":"9","author":"Bruserud \u00d8","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_6_18_2","first-page":"1497","article-title":"Effects of interleukin 13 on cytokine secretion by human acute myelogenous leukemia blasts","volume":"10","author":"Bruserud \u00d8","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1992.tb01589.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.1993.tb01695.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(84)90137-3"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1985.tb00956.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0198-8859(83)90050-2"},{"key":"e_1_2_6_24_2","unstructured":"SchmidtRE. Non\u2010lineage\/natural killer section report: new and previously defined clusters. In: Knapp W D\u00f6rken B Gilks WRet al. eds. Leukocyte Typing IV. Oxford:Oxford University Press 1989:51742."},{"key":"e_1_2_6_25_2","first-page":"55","article-title":"Different pathways of human T cell activation revealed by PHA\u2010P and PHA\u2010M","volume":"57","author":"O'flynn K","year":"1986","journal-title":"Immunology"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood.V74.5.1665.1665","article-title":"Lymphokine production by T cell clones after human bone marrow transplantation","volume":"74","author":"Velardi A","year":"1989","journal-title":"Blood"},{"key":"e_1_2_6_27_2","first-page":"69","article-title":"The proliferative T cell response to streptokinase","volume":"20","author":"Bruserud \u00d8","year":"1986","journal-title":"J Clin Lab Immunol"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.1983.tb00853.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.1988.tb02383.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1182\/blood.V88.9.3522.bloodjournal8893522","article-title":"Recognition of BCR\u2010ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR\u2010ABL breakpoint peptide","volume":"88","author":"TenBosch GJA","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_31_2","first-page":"123","article-title":"Immune surveillance of leukemia: rationale for immunotherapy","volume":"8","author":"Pawelec G","year":"1994","journal-title":"Haematol Rev"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.102.2.613"}],"container-title":["Scandinavian Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-3083.1998.00254.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-3083.1998.00254.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1365-3083.1998.00254.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-3083.1998.00254.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T05:54:41Z","timestamp":1694411681000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-3083.1998.00254.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1998,1]]}},"alternative-id":["10.1046\/j.1365-3083.1998.00254.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-3083.1998.00254.x","archive":["Portico"],"relation":{},"ISSN":["0300-9475","1365-3083"],"issn-type":[{"value":"0300-9475","type":"print"},{"value":"1365-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,1]]},"assertion":[{"value":"2002-01-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}